Case report: First Chinese patient with family partial lipodystrophy type 6 due to novel compound heterozygous mutations in the LIPE gene
Authors:
Open Access
- 24 July 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1417613
Abstract
Background: Family partial lipodystrophy (FPLD) is a rare autosomal dominant disease characterized by disorders of variable body fat loss associated with metabolic complications. FPLD6 has only been reported in a limited number of cases. Here, we reported a Chinese FPLD6 patient with compound heterozygous mutations in the lipase E, hormone-sensitive type (LIPE) gene.Case presentation: A 20-year-old female patient presented with hypertriglyceridemia, diabetes mellitus, hepatomegaly, and hepatic steatosis. Subcutaneous fat was significantly diminished in her face, abdomen, and limbs. The patient was assessed by detailed clinical and biochemical examinations. A liver biopsy showed severe lipodystrophy. In addition, there were retinal changes, peripheral nerve damage, and renal tubular injury. Sequencing was performed on extracted DNA. Genetic analysis revealed that the patient had compound heterozygous mutations in the LIPE gene: c.2497_250ldel (p.Glu833LysfsTer22) and c.2705del (p.Ser902ThrfsTer27) heterozygous mutations. Verification revealed that this mutation was inherited from her father and mother, respectively, and that they formed newly discovered compound heterozygous mutations occurring in the LIPE gene, causing FPLD6.Conclusion: We reported the first case of FPLD6 in China. Gene analysis demonstrated compound heterozygous mutations in LIPE in this patient. Our case emphasizes the importance of genetic testing in young patients with severe metabolic syndromes.Keywords
This publication has 31 references indexed in Scilit:
- Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN studyJournal of Clinical Lipidology, 2022
- A missense variant Arg611Cys in LIPE which encodes hormone sensitive lipase decreases lipolysis and increases risk of type 2 diabetes in American IndiansDiabetes/Metabolism Research and Reviews, 2021
- Lipodystrophic syndromes: From diagnosis to treatmentAnnales d'Endocrinologie, 2020
- Hormone-sensitive lipase is a retinyl ester hydrolase in human and rat quiescent hepatic stellate cellsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2019
- Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophyEndocrine, 2019
- Lipodystrophy SyndromesEndocrinology and Metabolism Clinics of North America, 2016
- Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathyAmerican Journal of Medical Genetics Part A, 2016
- SF-1 (NR5A1) expression is stimulated by the PKA pathway and is essential for the PKA-induced activation of LIPE expression in Y-1 cellsMolecular and Cellular Biochemistry, 2015
- A Novel LIPE Nonsense Mutation Found Using Exome Sequencing in Siblings With Late-Onset Familial Partial LipodystrophyCanadian Journal of Cardiology, 2014
- Metreleptin: First Global ApprovalDrugs, 2013